This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
All You Need to Know About VAXART, INC. (VXRT) Rating Upgrade to Buy
by Zacks Equity Research
VAXART, INC. (VXRT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
VAXART, INC. (VXRT) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
VAXART, INC. (VXRT) delivered earnings and revenue surprises of 6.67% and -9.91%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: VAXART, INC. (VXRT) Q3 Earnings Expected to Decline
by Zacks Equity Research
VAXART, INC. (VXRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vaxart (VXRT) Starts Recruitment in Oral COVID-19 Vaccine Study
by Zacks Equity Research
Vaxart (VXRT) commences recruiting subjects in its mid-stage study for its oral vaccine tablet for COVID-19. It will begin dosing in the United States later this month.
Vaxart (VXRT) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Vaxart (VXRT) has been struggling lately, but the selling pressure may be coming to an end soon.
Is the Options Market Predicting a Spike in Vaxart (VXRT) Stock?
by Zacks Equity Research
Investors need to pay close attention to Vaxart (VXRT) stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in Vaxart (VXRT) Stock?
by Zacks Equity Research
Investors need to pay close attention to Vaxart (VXRT) stock based on the movements in the options market lately.
VAXART, INC. (VXRT) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
VAXART, INC. (VXRT) delivered earnings and revenue surprises of 7.14% and -79.64%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate VAXART, INC. (VXRT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
VAXART, INC. (VXRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vaxart (VXRT) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On Vaxart's (VXRT) second-quarter earnings call, investors are set to mainly focus on updates on the company's progress with oral vaccine candidates for COVID-19 and Norovirus.
Vaxart (VXRT) Enters an Agreement With Altesa for Antiviral
by Zacks Equity Research
Vaxart (VXRT) enters a licensing agreement with Altesa Biosciences, Inc., whereby the latter gets rights to develop, manufacture and commercialize vapendavir.
Implied Volatility Surging for Vaxart (VXRT) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Vaxart (VXRT) stock based on the movements in the options market lately.
Do Options Traders Know Something About Vaxart (VXRT) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Vaxart (VXRT) stock based on the movements in the options market lately.
VAXART, INC. (VXRT) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
VAXART, INC. (VXRT) delivered earnings and revenue surprises of -40.00% and -17.99%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
VAXART, INC. (VXRT) Moves 5.6% Higher: Will This Strength Last?
by Zacks Equity Research
VAXART, INC. (VXRT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
VAXART, INC. (VXRT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, VAXART, INC. (VXRT) closed at $6.79, marking a -0.73% move from the previous day.
VAXART, INC. (VXRT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
VAXART, INC. (VXRT) closed the most recent trading day at $7.94, moving -1.85% from the previous trading session.
Hedge Fund Diaries: Who Was Buying Your Stocks?
by Kevin Cook
SEC 13Fs reveal trades from months ago, but also patterns of long-term bullish behavior.
Vaxart (VXRT) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Vaxart's (VXRT) fourth-quarter earnings call, investor focus will be on the company's progress with the development of its oral COVID-19 vaccine candidate, VXA-CoV2-1.
Biotech Bonanza: COVID Launches Science at Warp Speed
by Kevin Cook
From vaccines to diagnostics, the opportunities in biotechnology are rich for those who do their homework.
Do Options Traders Know Something About Vaxart (VXRT) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Vaxart (VXRT) stock based on the movements in the options market lately.
Emergent (EBS) Posts Preliminary '20 Results, Gives 2021 View
by Zacks Equity Research
Emergent (EBS) tightens revenue view for 2020 and expects a consistent rise in sales of contract development and manufacturing services provided to other companies.
4 Small COVID-19 Vaccine Makers to Look Out for in 2021
by Kinjel Shah
Here we discuss four small biotech companies, NVAX, CVAC, VXRT and ARCT, that are making COVID-19 vaccine candidates, which may be approved in 2021, if successfully developed, and bring profits.
Do Options Traders Know Something About Vaxart (VXRT) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Vaxart (VXRT) stock based on the movements in the options market lately.
The Zacks Analyst Blog Highlights: INO, NVAX, TBIO and VXRT
by Zacks Equity Research
The Zacks Analyst Blog Highlights: INO, NVAX, TBIO and VXRT